National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
ID: 358230Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358230

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-353-Full-Announcement.html
    PAR-25-353.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity aimed at innovating treatments for mental disorders. This initiative encourages collaborations among academia, biotech, and pharmaceutical industries to expedite the discovery and testing of new pharmacologic and neuromodulation tools. The program funds multidisciplinary projects focusing on early-stage human studies and rationally based therapeutic candidates. Applications must follow specific instructions and meet eligibility criteria. Key dates include an opening submission date of January 25, 2025, with a total project period not exceeding five years. The NIH emphasizes the importance of data sharing and encourages novel approaches to treatment challenges in mental health. The NCDDG program is designed not to compete with the private sector but to complement it, with expectations for significant therapeutic impacts. Applications should demonstrate multidisciplinary expertise and provide clear, evaluative milestone plans for success assessment. Overall, the NCDDG program aims to transform mental health treatment through cooperative, innovative research efforts.
    Similar Opportunities
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity aimed at accelerating the development of device-based treatments for Substance Use Disorders (SUDs) under the UG3/UH3 Cooperative Agreement mechanism. This initiative invites applications focused on both pre-clinical and clinical development of neuromodulatory devices, with the goal of advancing these technologies through the FDA approval process. The funding is structured in two phases: the UG3 phase supports milestone achievements for up to $500,000 annually over two years, while the UH3 phase provides continued funding for projects that successfully meet these milestones for an additional three years. Interested applicants can find more information and application guidelines at the provided NIH link, with the submission deadline set for August 13, 2026.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Studies of Mental Illness (Collaborative R01)" aimed at supporting multidisciplinary clinical studies focused on mental health, particularly in areas such as genetics, biomarkers, and various mental illnesses. This initiative encourages collaboration across multiple sites to enhance sample sizes and diversity in participant recruitment, specifically targeting health disparity populations. The program allows for a project period of up to five years with no explicit budget limits, although proposed budgets must be well justified. Interested applicants, including various educational and nonprofit institutions, should submit their applications by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html.